8-K: Gilead Sciences Reports Mixed Q1 Results Amidst Acquisition Costs and Pipeline Progress

Gilead Sciences' first quarter results show revenue growth driven by HIV, Oncology and Liver Disease, but are impacted by significant acquisition-related charges.

Summary

• Gilead Sciences announced its first quarter 2024 financial results, with total revenue increasing by 5% to $6.7 billion compared to the same period in 2023.
• Product sales, excluding Veklury, grew by 6% year-over-year to $6.1 billion, driven by strong performance in HIV, Oncology, and Liver Disease.
• However, the company reported a diluted loss per share of $(3.34), compared to earnings of $0.80 in the same period last year, primarily due to a $3.9 billion charge related to the acquisition of CymaBay Therapeutics.
• Non-GAAP diluted loss per share was $(1.32), compared to earnings of $1.37 in the first quarter of 2023, also impacted by the CymaBay acquisition.
• Gilead's cash, cash equivalents, and marketable debt securities decreased to $4.7 billion as of March 31, 2024, from $8.4 billion at the end of 2023.
• The company generated $2.2 billion in operating cash flow, paid $990 million in dividends, and repurchased $400 million of common stock during the quarter.
• Gilead reaffirmed its full-year product sales guidance but lowered its diluted EPS guidance to $0.10-$0.50 and non-GAAP diluted EPS guidance to $3.45-$3.85.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant losses reported in the quarter, driven by acquisition-related charges and impairments. While there are positive aspects such as revenue growth in key areas, the overall financial performance and lowered guidance overshadow these positives.

Positives

• Product sales, excluding Veklury, showed a solid 6% year-over-year growth, indicating strength in the core business.
• Biktarvy sales increased by 10%, demonstrating continued market demand for this HIV treatment.
• Oncology sales grew by 18%, highlighting the success of Gilead's expansion into this therapeutic area.
• The Liver Disease portfolio saw a 9% increase in sales, driven by favorable inventory dynamics and demand.
• Gilead generated $2.2 billion in operating cash flow, showcasing the company's ability to generate cash.
• The company continues to invest in its pipeline with research collaborations and licensing agreements.

Negatives

• The company reported a significant diluted loss per share of $(3.34), primarily due to acquisition-related charges.
• Non-GAAP diluted loss per share was $(1.32), also impacted by the CymaBay acquisition.
• Cash, cash equivalents, and marketable debt securities decreased significantly from $8.4 billion to $4.7 billion.
• The acquired IPR&D charge of $3.9 billion and IPR&D impairment of $2.4 billion significantly impacted profitability.
• Veklury sales decreased by 3%, reflecting lower COVID-19 related hospitalizations.
• Descovy sales decreased by 5% due to lower average realized price.

Risks

• The company's financial results are subject to risks and uncertainties, including the amount and timing of Veklury revenues.
• There are risks associated with the company's ability to realize the potential benefits of acquisitions, collaborations, and licensing arrangements.
• Patent protection and estimated loss of exclusivity for products and product candidates pose a risk.
• Clinical trial results may not warrant further development of product candidates.
• Regulatory approvals may be delayed or not granted, and any approvals may have limitations on use.
• There are risks related to commercialization, manufacturing, supply chain, pricing, and reimbursement pressures.
• Market share and price erosion caused by generic versions of Gilead products are a concern.
• Physicians and patients may not see advantages of Gilead's products over other therapies.

Future Outlook

Gilead reaffirmed its full-year product sales guidance of $27.1 billion to $27.5 billion but lowered its diluted EPS guidance to $0.10-$0.50 and non-GAAP diluted EPS guidance to $3.45-$3.85. The company expects a regulatory decision on seladelpar in August.

Management Comments

• Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and Liver Disease, said Daniel ODay, Gilead's Chairman and Chief Executive Officer.
• The acquisition of CymaBay brings us another potentially transformative therapy for people with liver disease, and a regulatory decision on seladelpar is expected in August.
• New HIV data demonstrates the continued progress in our long-acting HIV pipeline, and we look forward to providing updates on this and our broad Oncology portfolio throughout the rest of 2024.

Industry Context

Gilead's results reflect the ongoing trends in the biopharmaceutical industry, including the importance of strategic acquisitions for pipeline expansion and the challenges of managing product lifecycles and competition. The focus on HIV, oncology, and liver disease aligns with key areas of unmet medical need and market growth. The impact of COVID-19 on Veklury sales highlights the volatility of pandemic-related revenues.

Comparison to Industry Standards

• Gilead's revenue growth of 5% is moderate compared to some high-growth biotech companies, but it is a solid performance for a large-cap pharmaceutical company.
• The 10% growth in Biktarvy sales is strong and indicates a continued competitive advantage in the HIV market, comparable to other leading HIV therapies.
• The 18% growth in oncology sales is impressive and positions Gilead as a growing player in this space, similar to companies like Bristol Myers Squibb and Merck which have also seen strong oncology growth.
• The significant IPR&D charges related to the CymaBay acquisition are not uncommon in the industry, as companies often pay a premium for promising pipeline assets, similar to other large acquisitions in the sector.
• The decrease in Veklury sales is consistent with the broader trend of declining COVID-19 related revenues across the industry, impacting companies like Regeneron and Pfizer.
• Gilead's cash position has decreased significantly, which is a concern, but is not unusual after a large acquisition, similar to other companies that have made large acquisitions.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the lower earnings per share and reduced guidance.
• Employees may be affected by restructuring expenses.
• Customers will benefit from the continued development of new therapies.
• Suppliers may see changes in demand based on product sales.
• Creditors will be impacted by the company's financial performance and cash position.

Next Steps

• Gilead will continue to advance its pipeline, including the development of seladelpar.
• The company will provide updates on its long-acting HIV pipeline and oncology portfolio throughout the rest of 2024.
• Gilead will host a conference call to discuss the results.
• The company will continue to monitor the market and adjust its strategies as needed.

Key Dates

Keywords

Gilead Sciences, Financial Results, Q1 2024, HIV, Oncology, Liver Disease, Biktarvy, Veklury, CymaBay, Acquisition, EPS, IPR&D, Seladelpar